SINGAPORE (Dec 5): iX Biopharma has been awarded a cannabis manufacture license from the Australian Office of Drug Control to manufacture and supply extracts and tinctures of cannabis and cannabis resins. The specialty pharmaceutical company’s wholly-owned subsidiary, iX Syrinx, operates a TGA cG...

SINGAPORE (May 9): iX Biopharma announced 3Q19 earnings of $7.8 million, compared to a loss of $3.9 million in 3Q18, due to a one-off gain from the disposal of a subsidiary. During the quarter, the group disposed its entire laboratory testing business held under Chemical Analysis for A$12.5 million...

IX Biopharma has entered into an agreement with independent third party Eurofins Australia New Zealand Holding for the proposed disposal of its entire stake in its wholly owned subsidiary, Chemical Analysis, for A$12.5 million (S$12 million) in cash.

THE following companies saw new developments that may affect trading of their shares on Monday:

IX Biopharma has entered into an agreement with independent third party Eurofins Australia New Zealand Holding for the proposed disposal of its entire stake in its wholly-owned subsidiary, Chemical Analysis, for A$12.5 million (S$12 million) in cash.

SINGAPORE (Feb 18): iX Biopharma is selling Chemical Analysis, its laboratory testing business in Australia, to Eurofins Australia New Zealand Holding for A$12.5 million ($12 million).   The consideration is about $10.6 million and $10.84 million over the book value and its net tangible asset valu...

SINGAPORE (Feb 12): Specialty pharmaceutical and nutraceutical firm iX Biopharma has reported a net loss of $3.6 million in 2Q19, an increase of 11% compared to a net loss of $3.2 million in 2Q18. This brings its net losses for 1H19 to $6.8 million, 7% higher than a net loss of $6.4 million in ...

PHARMACEUTICAL company iX Biopharma has sunk deeper into the red with a net loss of S$3.7 million for the second quarter ending Dec 31, 2018 from a net loss of S$3.2 million a year ago. For the six months ending Dec 31, the company saw a net loss of S$6.9 million from S$6.4 million a year ag...

Amid signs of slowing global growth and continued geopolitical tensions, The Edge Singapore’s 10 picks for the Year of the Pig are poised to rise above the fray SINGAPORE (Feb 4): At a recent presentation for wealth management clients organised by Oversea-Chinese Banking Corp, the attendees were ...

SINGAPORE (Feb 1): The Edge Singapore has assembled the annual portfolio of 10 stocks, done in conjunction with the Lunar New Year. Our selections are CapitaLand, DBS Group Holdings, iFast Corp, iX Biopharma, Mapletree Industrial Trust, MindChamps Preschool, NetLink NBN Trust, Raffles Medical Group...